Preoperative Predictive Value of Neuthrophil/Lymphocyte Ratios in Testicular Tumors

Öz

Objective: It has been demonstrated that neuthrophil/lymphocyte ratio is an independent prognostic factor in many cancers such as bladder tumor and renal tumor. Whether any differences neuthrophil/lymphocyte ratio regarding the pathological stage of testicular tumor was assessed in this study. Meterial and Methods: 21 patients underwent orchiectomy for testicular mass in our clinic were included to the study. Neuthrophil/lymphocyte ratios of both groups were obtained from preoperative blood count. Patients were divided into two groups as Group 1 and 2, which contain stage 1 and ≥stage 2 diseases, respectively. Neuthrophil/lymphocyte ratios of both groups were compared statistically using the Mann Whitney U test. Results: Pathologic examination revealed pure seminoma in 10 patients, mixt germ cell tumor in 6 patients, lymphoma in 1 patient, adenomatoid tumor in 1 patient, fibroma in 1 patient, small round cell ca in 1 patient and leydig cell tumor in 1 patient. Pathologic examination revealed benign pathology in 3 patients. There were 9 patients in each group. The mean neuthrophil/lymphocyte ratios for group 1 and 2 were 1.99 (SD: 0.779) and 2.74 (SD: 1.484), respectively. There was no statistically significant difference between both groups regarding the neuthrophil/lymphocyte ratio (p=0.270). Conclusion: Neuthrophil/lymphocyte ratio could not predict the pathological stage of testicular tumor preoperatively. Larger series and long-term follow-ups are needed to determine of prognostic effect of neuthrophil/lymphocyte ratio on testicular tumor. Key words: Testis; Seminoma; NLR; Prognosis.

Anahtar Kelimeler

• Testis; Seminoma; NLR; Prognosis.

Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri

Öz

Amaç: Nötrofil/Lenfosit oranının mesane kanseri ve böbrek tümörü gibi birçok kanserde bağımsız bir prognostik faktör olduğu gösterilmiştir. Bu çalışmada testis tümörlerinin farklı evrelerinde, Nötrofil/Lenfosit oranında herhangi bir değişim olup olmadığını tespit etmeyi amaçladık. Gereç ve Yöntemler: Kliniğimizde testis tümörü şüphesi ile orşiektomi yapılmış 21 hastanın patoloji sonuçları geriye dönük olarak incelendi. Tüm hastaların operasyon öncesi kan değerlerinden Nötrofil/Lenfosit oranları tespit edildi. Evre 1 hastalar grup 1 ve evre 2 ve üzeri hastalar grup 2 olarak sınıflandırıldı. Her grupta 9' ar hasta mevcuttu. Her iki grubun da Nötrofil/Lenfosit oranları Mann-Whitney U testi kullanılarak istatistiksel olarak karşılaştırıldı. Bulgular: Patolojik inceleme sonucunda 10 hastada saf seminom, 6 hastada miks germ hücreli tümör, 1 hastada lenfoma, 1 hastada adenomatoid tümör, 1 hastada fibroma, 1 hastada small round cell ve 1 hastada ise leydig hücreli tümör tespit edildi. Her bir grupta 9 hasta bulunmaktaydı. Grup 1 ve 2 ‘nin ortalama Nötrofil/Lenfosit oranları sırasıyla, 1.99 (SD: 0.779) ve 2.74 (SD: 1.484) idi. Nötrofil/Lenfosit oranları açısından bakıldığında bu iki grup arasında anlamlı bir fark olmadığı saptandı (p=0.270). Sonuç: Nötrofil/Lenfosit oranları testis tümörünün evresini operasyon öncesinden tahmin edememektedir. Ancak Nötrofil/Lenfosit oranlarının testis tümöründeki prognostik değerinin ortaya çıkarılması için daha geniş serilere ve daha uzun hasta takip sürelerinde ihtiyaç vardır. Anahtar kelimeler: Testis; Seminom; NLR; Prognoz.

Anahtar Kelimeler

• Testis; Seminom; NLR; Prognoz.

Kaynakça

1. Ferlay J, Shin H.R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 IntJ Cancer 2010;127:2893-917.
2. Okutur K, Demir G. Testis tümörlerinin sistemik kemoterapisine bağlı erken ve geç yan etkiler. Üroonkoloji Bülteni 2008;3:10—14.
3. Hahn NM, Sweeney CJ. Germ cell tumors: an update of recent data and review of active protocols in stage | and metastatic disease. Urol Oncol 2005;23:293-302.
4. Diamantopoulos N, Kortsaris A. Testicular germ cell tumors. J BUON 201 O;15:421—34.
5. Van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIA. Chest 2000;117:374—9.
6. Leman ES, Gonzalgo ML. Prognostic features and markers for testicular cancer management. Indian J Urol 2010;26:76-81.
7. Yamanaka T, Matsumoto S, Teramukai S, lshiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215—20.
8. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for lL—2 immunotherapy. J lmmunother 2003;26:394—402.

9. Yalçınkaya U, Çalışır B, Uğraşı N, Filiz G, Erol O. Testis tümörleri: 30 yıllık arşiv tarama sonuçları. Türk Patoloji Dergisi 2008;24:100—6.
10. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz—Ares L,
11. Arranz JA, Guma J et al. Clinical pattern and therapeutic
12. results achieved n 1490 patients with germ—cell tumors of
13. the testis: the experience of the Spanish Germ-Cell Cancer
14. Group (GG). Eur Urol 2002;42:553-63.
15. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: An overview. Int J Cancer 2005;116:331—9.
16. Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277—308.
17. von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377—427.
18. Trigo JM, Tabernero JM, Paz—Ares L, Garcia-Llano JL, Mora
19. J, Lianes P et al. Tumor markers at the time of recurrence in
20. patients with germ cell tumors. Cancer 2000;88:162—8.
21. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al. 18F—FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.
22. Gibson PH, Cuthbertson BH, Croal BL, Rae D, El—Shafei H, Gibson G et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new—onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010;105:186—91.
23. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K et al. Pretreatment neutrophil counts as an independent prognostic factor in advanced non—small cell lung canceran analysis of Japan multinational trial organization LCOO-O3. Eur J Cancer 2009;45:1950—8.
24. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J et al. Prognostic factors for survival in advanced non—small—cell lung cancerzunivariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer
25. Working Party. J Clin Oncol 1995;13:1221—30.
26. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation—based prognostic score in patients with metastatic renal cancer. Cancer 2007;109:205- 12.
27. Symbas NP, Townsend MF, El—Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000;86:203-7.
28. Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J 2010;123:3438-43.